EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial

Sara Massetti, Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis, Anneke Muller Kobold, Eleni T Tzavara, Peter Meerlo, Robert A Schoevers, Jens H van Dalfsen

Journal of Affective Disorders · 2026-11 · 413 · 122265

DOI: 10.1016/j.jad.2026.122265 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026-11. Verfasst von Sara Massetti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands. Electronic address: s.massetti@umcg.nl. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Ketamine, Depressive Disorder, Treatment-Resistant, Antidepressive Agents. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health~Holland, Netherlands Organisation for Health Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorKetamineDepressive Disorder, Treatment-ResistantAntidepressive AgentsHumansFemaleMaleAdministration, OralAdultMiddle AgedTreatment OutcomePsychiatric Status Rating ScalesDouble-Blind MethodSeverity of Illness Index

Stichwörter der Autor:innen

Brain-derived neurotrophic factorClinical trialEsketamineMajor depressive disorder

Substanzen

Brain-Derived Neurotrophic FactorKetamineEsketamineAntidepressive AgentsBDNF protein, human

Autor:innen und Institutionen

  • Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands. Electronic address: s.massetti@umcg.nl.
  • Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands.
  • Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands; Department of Mood Disorders, PsyQ Haaglanden, Parnassia Psychiatric Institute, The Hague, the Netherlands.
  • Department of Laboratory Medicine, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
  • Université Paris Cité, Inserm, CNRS, HealthFex, F-75006, Paris, France.
  • Neurobiology Expertise Group, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands.

Förderung

  • Health~Holland
  • Netherlands Organisation for Health Research and Development

Zitieren

APA

Massetti, S., Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., Muller Kobold, A., Tzavara, E. T., Meerlo, P., Schoevers, R. A., & van Dalfsen, J. H. (2026). Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial. Journal of Affective Disorders, 413, 122265. https://doi.org/10.1016/j.jad.2026.122265

Vancouver

Massetti S, Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, Muller Kobold A, Tzavara ET, et al. Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial. Journal of Affective Disorders. 2026;413:122265. doi:10.1016/j.jad.2026.122265

BibTeX
@article{Massetti2026,
  author = {Massetti, Sara and Smith-Apeldoorn, Sanne Y and Veraart, Jolien K E and Kamphuis, Jeanine and Muller Kobold, Anneke and Tzavara, Eleni T and Meerlo, Peter and Schoevers, Robert A and van Dalfsen, Jens H},
  title = {Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {413},
  pages = {122265},
  doi = {10.1016/j.jad.2026.122265}
}
Kostenlos starten →